What is the recommended management for Morton's neuroma?

Management of Morton's Neuroma

For Morton's neuroma, begin with ultrasound-guided corticosteroid plus local anesthetic injection, which provides superior pain relief and functional improvement compared to non-guided injection, and reserve surgical neurectomy for cases failing 3-6 months of conservative management.

Diagnostic Confirmation

Before initiating treatment, confirm the diagnosis with imaging:

• MRI is the preferred imaging modality with 93% sensitivity and 68% specificity for detecting Morton's neuroma 11
• High-resolution ultrasound is equally effective (90% sensitivity, 88% specificity) and offers the advantage of real-time clinical correlation during examination 11
• Both modalities show no significant diagnostic differences, though ultrasound may have slightly superior diagnostic capabilities 1
• Gadolinium contrast is not essential but may improve soft-tissue visualization 1

First-Line Treatment: Ultrasound-Guided Injection

Ultrasound-guided corticosteroid plus local anesthetic (UG CS+LA) is the evidence-based first-line intervention:

• Reduces pain by 15 points on VAS compared to non-guided injection (moderate-certainty evidence) 2
• Improves function significantly (SMD -0.47) 2
• Increases patient satisfaction 1.71-fold compared to non-guided technique 2
• Adverse events are minimal (4.9% depigmentation or fat atrophy) 2

Important Caveat About Corticosteroid Injections

While corticosteroid injections are effective, the addition of corticosteroid to local anesthetic alone may provide little additional benefit at 3-6 months (pain reduction only -6.31 mm, not clinically significant) 2. However, the ultrasound guidance itself appears to be the critical factor driving superior outcomes, not simply the corticosteroid component.

Alternative Non-Surgical Options

If corticosteroid injection fails or is contraindicated, consider these alternatives in order:

Second-Line: Radiofrequency Ablation

• Use temperature ≥85°C with ≤3 cycles for optimal results 3
• Provides significant pain reduction (VAS improvement of 6.97 points at higher temperatures) 3
• 47.6% achieve complete pain relief at final follow-up 3
• Minimal complications (2.1%) 3
• More effective than lower temperature settings or multiple cycles 3

Third-Line: Sclerosing Injections

• Alcohol injections show promising short-term results 4
• Evidence quality is limited but demonstrates efficacy 54

Emerging Options with Limited Evidence

• Capsaicin injection: 51.8% VAS reduction 5
• Cryoablation: Shows promise but needs more rigorous trials 4
• Extracorporeal shockwave therapy: Inconsistent results 6

Surgical Management

Reserve neurectomy for patients failing 6-12 months of non-surgical treatment 72:

• Surgical excision shows better long-term outcomes than conservative treatment in systematic reviews 7
• No significant difference between plantar versus dorsal approach - use the approach you're most comfortable with 8
• Both approaches show approximately 75-78% substantial pain improvement 8
• Complete pain relief occurs in <50% of cases 8

For Recurrent Neuromas

• Consider collagen conduit technique with 85% patient satisfaction 8
• Reduces need for deep dissection and associated morbidity 8
• Pass conduit dorsally into intermetatarsal space and secure to dorsal fascia 8

Treatment Algorithm

1. Confirm diagnosis with ultrasound or MRI 11
2. First attempt: Ultrasound-guided corticosteroid + local anesthetic injection 2
3. If inadequate response at 3-6 months: Radiofrequency ablation at ≥85°C 3
4. If still symptomatic at 6-12 months: Surgical neurectomy (dorsal or plantar approach) 78
5. For recurrent post-surgical neuroma: Revision with collagen conduit 8

Critical Pitfalls to Avoid

• Don't perform non-guided corticosteroid injections - ultrasound guidance significantly improves outcomes 2
• Don't use radiofrequency ablation at <85°C or >3 cycles - this reduces efficacy 3
• Don't rush to surgery - allow adequate trial of non-surgical management (6-12 months minimum) 7
• Monitor for corticosteroid complications: skin atrophy (3.9%), hypopigmentation (3.9%), plantar fat pad atrophy (2.6%) 2